El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Crinetics Pharmaceuticals Inc
Cerrado
SectorSalud
44.94 0.47
Resumen
Variación precio
24h
Mínimo
43.91
Máximo
46.22
Ingresos | -14M -130M |
|---|---|
Ventas | -888K 143K |
Margen de beneficio | -90,972.727 |
Empleados | 437 |
EBITDA | -12M -142M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +88.59% upside |
Próximas Ganancias | 26 feb 2026 |
|---|
Capitalización de Mercado | 1B 5.1B |
|---|---|
Apertura anterior | 44.47 |
Cierre anterior | 44.94 |
Noticias sobre sentimiento de mercado
By Acuity
38%
62%
106 / 352 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Weak Bullish Evidence
Crinetics Pharmaceuticals Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Crinetics Pharmaceuticals Inc Esperado
Precio Objetivo
By TipRanks
88.59% repunte
Estimación a 12 meses
Media 89.45 USD 88.59%
Máximo 105 USD
Mínimo 67 USD
De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
106 / 352 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Live chat